US-based medical device firm St Jude Medical has secured CE mark approval for three new Quartet left ventricular (LV) leads, providing physicians with additional electrode spacing options and one new lead shape.

The additional spacing combinations will allow physicians to target the individual cardiac anatomies of patients who require support from cardiac resynchronisation therapy pacemakers (CRT-P) and defibrillators (CRT-D).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new quadripolar leads can be used with next-generation MultiPoint Pacing technology, which allows physicians to pace several locations on the left side of the heart.

“We are now able to place the quadripolar lead in the best possible location for that patient.”

Additionally, the technology helps physicians to provide a new option for patients who haven’t responded to CRT.

Helsinki University Central Hospital cardiologist Dr Sami Pakarinen said: “Heart and blood vessel anatomy vary from patient to patient so having multiple sizes and spacing options with the Quartet quadripolar lead helps me to treat all of my patients in need of cardiac resynchronisation therapy.

“We are now able to place the quadripolar lead in the best possible location for that patient, capturing more cardiac tissue to give heart failure patients the best opportunity to respond.”

According to previous studies CRT is known to improve the quality of life for many patients with heart failure.

It resynchronises the beating of the heart’s lower chambers, which often beat out of sync in heart failure patients.

The design of the new leads is based on the company’s quadripolar LV lead technology, and they feature additional spacing options on two new S-shape and one new double-bend lead designs.

St Jude Medical medical director and vice-president of medical affairs Dr Philip Adamson said: “These lead choices allow physicians to identify what lead spacing option will work best for each patient so they can individualise care.

“The expanded selection of quadripolar pacing leads reinforces St Jude Medical’s leadership in quadripolar pacing and heart failure treatment options.”

The company noted that some of the newly approved products are also magnetic resonance (MR)-conditional, including the Quadra Assura CRT-D and Quadra Assura MP CRT-D with MultiPoint pacing.

Physicians can also customise therapy using the Auto Vect Quartet test, which is designed to automatically guide programming of appropriate therapy options available and streamline workflow.

Image: Quartet quadripolar pacing leads. Photo: courtesy of St Jude Medical.